AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Portfolio Pulse from
AIM ImmunoTech has received approval from NYSE American for its plan to regain compliance with stockholders' equity requirements. The company has until June 11, 2026, to meet the NYSE's Continued Listings Standards.
February 26, 2025 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech's plan to regain compliance with NYSE American's equity requirements has been accepted, giving the company until June 11, 2026, to meet the standards.
The acceptance of AIM's compliance plan by NYSE American is a positive development, as it provides the company with a clear path and timeline to meet listing standards, potentially stabilizing investor confidence and supporting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100